Featured Research

from universities, journals, and other organizations

Nano-syringe delivers combination, targeted brain cancer therapy

Date:
April 16, 2012
Source:
Methodist Hospital, Houston
Summary:
Nanomedicine researchers have developed a way to selectively kill brain cancer cells by using a tiny syringe to deliver a combination of chemotherapy drugs directly into the cells.

Dr. David Baskin, neurosurgeon, Methodist Neurological Institute and Martyn Sharpe, lead author and researcher, Methodist Neurological Institute.
Credit: Image courtesy of Methodist Hospital, Houston

Nanomedicine researchers at the Methodist Neurological Institute and Rice University have developed a way to selectively kill brain cancer cells by using a tiny syringe to deliver a combination of chemotherapy drugs directly into the cells. These findings will be published in the April 24 issue of the American Chemical Society journal ACS Nano.

Patients with glioblastoma multiforme (GBM), the most common and aggressive malignant primary brain tumor, typically have a prognosis of 14-month median survival time despite medical interventions, which currently include surgery, chemotherapy and radiation.

The Rice-Methodist group developed the hydrophilic carbon cluster (HCC) antibody drug enhancement system (HADES), named after the Greek god of the underworld. Through a 20-nanometer syringe, which is 2 million times smaller than a coffee mug, this nanovector successfully delivered a combination of three chemotherapy drugs into GBM cells in vivo, resulting in a high kill rate.

"Without our nano-delivery system, we know that current drug delivery would be highly toxic to patients if we tried to deliver all three of these drugs at once," said David Baskin, M.D., neurosurgeon at the Methodist Neurological Institute, who began his nanomedicine research in 2004 with the late Nobel laureate and Rice chemist Richard Smalley. "But delivered in combination using these nano-syringes, our research demonstrated extreme lethality, with at least a three-fold increase in the number of dead cancer cells following treatment. The nano-syringes selectively deliver these drugs only to cancer cells, and appear not to be toxic to normal neurons and other non-cancerous brain cells."

HCCs are nanovectors with protective antioxidant properties, capable of transporting and delivering drugs and bioactive molecules. In order to bring the drug carriers close enough to the cancer cells and successfully deliver the chemotherapy combination, three different antibodies were combined with the HCC to allow the nanoparticle to stick to the cell membrane. The drugs stayed inside the HCC until it attached to the cell membrane. Once binding occurred, the drugs were released into the fatty (lipid) environment in the membrane. The chemical properties of the chemotherapy drugs inside the HCC are such that they prefer to accumulate in areas with high concentrations of lipids and avoid areas with high water content, such as the extracellular space.

"A new and exciting advance is that now we have a carrier with protective properties, unlike previous nanotubes which were shown to be toxic," said Martyn Sharpe, the paper's lead author and a scientist with the Methodist NI's department of neurosurgery. "Some of the chemotherapy agents used in this research traditionally perform poorly with GBMs. Now that we've shown a successful kill rate of these cells in vivo, we're looking at treating human tumors that will be grown in immune-compromised mice models."

As personalized medicine continues to evolve, Baskin says this research could also be significant for other forms of cancer, including breast and head and neck cancers.

The paper represents an important collaboration between the laboratories of Baskin at Methodist, and James Tour, Ph.D. with Rice University's Smalley Institute for Nanoscale Science. Further work developing this system and expanding its utility is under way with continued collaboration between these two research groups.

The research was supported by The Henry J. N. Taub Fund for Neurological Research, The Pauline Sterne Wolff Memorial Foundation, Golfers Against Cancer, The Taub Foundation, The Verdant Foundation Limited and The Methodist Hospital Foundation.


Story Source:

The above story is based on materials provided by Methodist Hospital, Houston. Note: Materials may be edited for content and length.


Journal Reference:

  1. Martyn A. Sharpe, Daniela C. Marcano, Jacob M. Berlin, Marsha A. Widmayer, David S. Baskin, James M. Tour. Antibody-Targeted Nanovectors for the Treatment of Brain Cancers. ACS Nano, 2012; 120313152927000 DOI: 10.1021/nn2048679

Cite This Page:

Methodist Hospital, Houston. "Nano-syringe delivers combination, targeted brain cancer therapy." ScienceDaily. ScienceDaily, 16 April 2012. <www.sciencedaily.com/releases/2012/04/120416165829.htm>.
Methodist Hospital, Houston. (2012, April 16). Nano-syringe delivers combination, targeted brain cancer therapy. ScienceDaily. Retrieved July 22, 2014 from www.sciencedaily.com/releases/2012/04/120416165829.htm
Methodist Hospital, Houston. "Nano-syringe delivers combination, targeted brain cancer therapy." ScienceDaily. www.sciencedaily.com/releases/2012/04/120416165829.htm (accessed July 22, 2014).

Share This




More Health & Medicine News

Tuesday, July 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins